11
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Human Immunodeficiency Virus Type 1 Tat-Mediated Cytotoxicity of Human Brain Microvascular Endothelial Cells

, , &
Pages 584-593 | Published online: 10 Jul 2009
 

Abstract

Human immunodeficiency virus (HIV)-1 infection is often complicated with neurologic disorders, but the pathogenesis of HIV-1 encephalopathy is incompletely understood. Tat (HIV-1 transactivator protein) is released from HIV-1–infected cells and has been detected in the sera and cerebrospinal fluid of HIV-1–infected patients. Tat, along with increased inflammatory cytokines such as interferon-gamma (IFN-γ), have been implicated in the pathogenesis of HIV-1–associated blood-brain barrier dysfunction. The present study examined the effects of Tat and IFN-γ on human brain microvascular endothelial cells (HBMECs), which constitute the blood-brain barrier. Tat produced cytotoxicity of HBMECs, but required IFN-γ. IFN-γ treatment of HBMECs up-regulates vascular endothelial growth factor receptor-2 (VEGFR2/KDR), which is known to be the receptor for Tat. Tat activated KDR in the presence of IFN-γ, and Tat-mediated cytopathic changes involve its interaction with KDR and phosphatidylinositol 3-kinase (PI3K). Further understanding and characterization of Tat-HBMEC interactions should help us understand HIV-1 neuropathogenesis and develop strategies to prevent HIV-1 encephalopathy.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.